Subscribe

Atezolizumab First PD-L1 Inhibitor Approved by the FDA for Advanced or Metastatic Urothelial Cancer

Web Exclusives - FDA Approvals
Lilly Ostrovsky
Medical Writer

On May 18, 2016, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq; Genentech) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or after platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.   

“Tecentriq provides these patients with a new therapy targeting the PD-L1 pathway. Products that block PD-1/PD-L1 interactions are part of an evolving story about the relationship between the body’s immune system and its interaction with cancer cells,” said Richard Pazdur, MD, Director of the FDA’s Office of Hematology and Oncology Products.

The approval of atezolizumab was based on the results of the IMvigor 210 study, an open-label, multicenter, single-arm, phase 2 study involving 310 patients with locally advanced or metastatic urothelial carcinoma who received 1200 mg of atezolizumab intravenously. The study’s primary end point was objective response rate (ORR), and the secondary end point was the duration of response.

Atezolizumab conferred an ORR of 14.8%, with a median duration of response lasting more than 2.1 months and exceeding 13.8 months. The ORR was 9.5% in patients with programmed death ligand 1 (PD-L1) expression <5%, and the ORR was 26% in patients with PD-L1 expression ≥5%, suggesting that the level of PD-L1 expression may help identify patients who are more likely to respond to therapy with atezolizumab.

On the same day, in conjunction with this approval, the FDA approved the Ventana PD-L1 (SP142) assay, a companion diagnostic that detects the expression of PD-L1 levels on the tumor, which can help clinicians identify patients who would benefit most from atezolizumab treatment. Although all patients in the study showed some tumor shrinkage with the drug, the greater impact was seen in patients with PD-L1 expression.

The most common (≥20%) adverse reactions (all grades) associated with atezolizumab included fatigue (52%), decreased appetite (26%), nausea (25%), urinary tract infection (22%), pyrexia (21%), and constipation (21%). The most common (≥4%) grade 3/4 adverse reactions included abdominal pain (4%), fatigue (6%), urinary tract infection (9%), and dyspnea (4%).

Atezolizumab received a breakthrough therapy designation, priority review, and accelerated approval for this indication, all of which are designed to expedite the development and review of certain new drugs that may benefit patients with serious or life-threatening conditions.

Related Items
FDA Approvals of Brand-Name Prescription Drugs, January 1, 2019, Through June 15, 2020
August 2020 Vol 13, Eleventh Annual Payers' Guide published on September 9, 2020 in FDA Approvals
Imbruvica (Ibrutinib) Receives Expanded Indication, in Combination with Rituximab, as First-Line Treatment for Chronic Lymphocytic Leukemia
August 2020 Vol 13, Eleventh Annual Payers' Guide published on September 9, 2020 in FDA Approvals
Mayzent (Siponimod) Approved for Relapsing Forms of Multiple Sclerosis, Including Active Secondary Progressive Disease
August 2020 Vol 13, Eleventh Annual Payers' Guide published on September 9, 2020 in FDA Approvals
Pemazyre (Pemigatinib) First Targeted Therapy FDA Approved for Cholangio­carcinoma with FGFR2 Biomarker
August 2020 Vol 13, Eleventh Annual Payers' Guide published on September 9, 2020 in FDA Approvals
Tazverik (Tazemetostat) First FDA-Approved Treatment Specifically for Patients with Epithelioid Sarcoma
August 2020 Vol 13, Eleventh Annual Payers' Guide published on September 9, 2020 in FDA Approvals
Last modified: February 14, 2019
Copyright © Engage Healthcare Communications, LLC. All rights reserved.